Despite the clinical benefits of combination antiviral therapy, whether maximal antiviral potency has been achieved with current drug combinations remains unclear. We studied the first phase of decay of human immunodeficiency virus type 1 (HIV-1) RNA in plasma, one early indicator of antiviral activity, after the administration of a novel combination of lopinavir/ritonavir, efavirenz, tenofovir disoproxil fumarate, and lamivudine and compared it with that observed in matched cohorts treated with alternative combination regimens. On the basis of these comparisons, we conclude that the relative potency of highly active antiretroviral therapy may be augmented by as much as 25%-30%. However, it is important to emphasize that further study is warranted to explore whether these early measurements of relative efficacy provide long-term virologic and clinical benefits. Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted.
viduals [3] . This inability, as well as the persistence of a pool of latently infected CD4 ϩ T cells harboring infectious virus, are 2 clearly identified immediate obstacles to the development of alternatives to life-long treatment of HIV-1-infected individuals with HAART [4] . The ability of current antiviral therapy to suppress HIV-1 replication could be improved, in theory, by an increase in drug efficacy (defined as the ability to suppress in vivo production of infectious virions). After HAART is initiated, a rapid and exponential decrease in the plasma virus load occurs, referred to as the "first phase" of viral decay [5] . This first phase represents the clearance of free plasma HIV-1 virions and the death of productively HIV-1-infected CD4 ϩ T cells. Because the clearance of plasma virions is extremely rapid and thus negligible (compared with the rate of clearance of cells producing these particles), the rate of change or slope of the first phase of plasma HIV-1 decay is the product of 2 parameters: d, the decay constant of productively infected CD4 ϩ T cells, and , efficacy, the ability of the intervention to suppress viral replication. If we assume that the rate of decay of virusproducing CD4 ϩ T cells, d, is constant in comparable patient cohorts, then the slope of the first phase is directly proportional to the efficacy of the intervention applied [6] . Therefore, the more negative the slope of the first phase of HIV-1 RNA decay, the greater the efficacy of the antiretroviral therapy being used.
To explore whether the efficacy of HAART can be augmented, we studied early virologic events indicative of antiviral activity after the administration of a novel combination of lopinavir/ ritonavir (533/133 mg twice daily), efavirenz (600 mg daily), tenofovir disoproxil fumarate (300 mg daily), and lamivudine (150 mg twice daily) (regimen A). The average initial rate of decrease in plasma HIV-1 RNA, the first-phase slope, was compared to the decreases observed in matched individuals treated with 2 different HAART regimens. The first comparator, the group receiving regimen B, included subjects treated during acute and early HIV-1 infection with lamivudine (150 mg twice daily), abacavir (300 mg twice daily) in combination with indinavir (800 mg 3 times daily), and amprenavir (900 mg twice daily). The second comparator, the group receiving regimen C, included subjects treated during chronic infection with zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily) in combination with ritonavir (400-600 mg twice daily) and saquinavir (400-600 mg twice daily).
SUBJECTS AND METHODS
Forty-four individuals, 39 antiretroviral naive and 5 treatment experienced, were enrolled and began receiving treatment with regimen A between July 2000 and August 2001. Subjects were divided into 2 groups, those with acute and early infection ( ) and those with chronic infection ( ). By defin p 33 n p 11 nition, "acute and early infection" included subjects who tested positive for HIV-1 RNA; had no antibody response or an evolving response to HIV-1 infection or a documented negative serologic test result for HIV-1 antibodies within 120 days of screening; and had a clinical history compatible with new infection. Identical entry criteria were used to identify 29 subjects who were enrolled and began receiving treatment with regimen B between March 1997 and June 1998. A total of 9 individuals were excluded from the analysis as a result of inadequate data collection or known treatment adherence issues.
Of the 33 newly infected individuals who received treatment with regimen A, 6 subjects were excluded from the analysis as a result of nonadherence or inadequate data collection. Of the remaining 27, we selected 20 subjects for inclusion in the analysis who had baseline CD4 ϩ T cell counts and pretreatment HIV-1 RNA levels that most closely matched those of the 20 patients treated during acute and early infection with regimen B. Eleven patients who received treatment with regimen C during chronic infection and who had matching baseline CD4 ϩ T cell counts and HIV-1 RNA levels served as controls for the 11 chronically infected subjects who were treated with regimen A. In all of these studies, adherence was assessed mainly by history and drug reconciliation. Failure of patients to report taking all prescribed doses of all medications at the appropriate times during the initial 7-day period of treatment was considered to indicate nonadherence. Baseline characteristics were analyzed using the Mann-Whitney U test. was considered to be statistically P р .05 significant.
Plasma samples from all study subjects receiving regimens A and B were subjected to reverse-transcription polymerase chain reaction and sequencing of pol, using Trugene (Visible Genetics) in accordance with the manufacturer's instructions. In addition, viral phenotypes were identified using a commercial recombinant virus assay (Virologic).
The mean baseline (day 0) to day 7 viral decay slopes were determined using methods published elsewhere [5] and analyzed with the Mann-Whitney U test. The relative efficacies of the treatment regimens were calculated by dividing the mean day-0-7 HIV-1 decay slope of each of the matched treatment groups (regimens B and C) by the mean day-0-7 decay slope for patients treated with regimen A.
To more accurately characterize early virologic events that occurred after initiation of treatment, 9 chronically HIV-1-infected subjects were enrolled in a viral dynamics substudy in which plasma HIV-1 RNA was determined every 6 h for the first 72 h and then daily until day 10. For each participant in the viral dynamics substudy, the first-phase plasma HIV-1 RNA decay slope was calculated by nonlinear least-squares fitting of the 2-compartment (long-lived infected cell) or 3-compartment (latently and long-lived infected cell) model of HIV-1 decay to the data, as described elsewhere [7] . This procedure is more accurate than simple linear regression for analyzing the slope of the first phase of decay, because it does not rely on an arbitrary assignment of the end of the first phase.
RESULTS
The baseline characteristics of the subjects treated during acute and early and chronic infection were comparable (table 1). The vast majority of participants were men who have sex with men (98%). Phenotyping of viruses from all patients treated with regimens A and B indicated that the viruses were drug susceptible, and genotype analyses were consistent with wild-type HIV-1. The chronically infected individuals treated with the ritonavir and saquinavir-based regimen C were drug naive and began receiving therapy in June 1996.
Mean baseline plasma HIV-1 RNA levels (‫ע‬SE) in the acute and early cohorts treated with regimens A and B were 5.6 ‫ע‬ log 10 copies/mL (range, 4.2-7.2 log 10 copies/mL) and 0.2 log 10 copies/mL (range, 3.8-6.8 log 10 copies/mL), re-5.4 ‫ע‬ 0.2 spectively (table 1) . There were no statistically significant dif- for patients with acute and early infection treated with regimen A were significantly more negative than those calculated in the comparator study (regimen B) ( ; figure 1A) . P p .02 Using the slope obtained for the novel 4-drug regimen (regimen A) as a reference, we calculated that the control regimen (regimen B) had a relative efficacy of 0.75. In other words, the control regimen was 75% as effective in interrupting the production of infectious virions as was the novel drug combination regimen.
In the 22 chronically infected patients treated with regimens A and C, baseline characteristics included mean pretreatment HIV-1 RNA levels (‫ע‬SE) of log 10 copies/mL (range, 4.7 ‫ע‬ 0.2 4.0-5.9 log 10 copies/mL) and log 10 copies/mL (range, 4.9 ‫ע‬ 0.2 3.9-5.9 log 10 copies/mL), respectively ( ; 1B ). Using the rate of change in HIV-P ! .05 1 RNA levels obtained with regimen A as a reference, we calculated that the relative efficacy of regimen C was 0.68, or 68%.
Interestingly, despite obvious differences in baseline characteristics, including a statistically significant different in baseline HIV-1 RNA levels, there appears to be no substantial difference between the mean slope observed for subjects treated with regimen A during acute and early infection (Ϫ0.52 d
Ϫ1
) and those treated with regimen A during chronic infection (Ϫ0.54 d
). We calculated the mean first-phase slope of HIV-1 RNA decay using methods published elsewhere [8] in the 9 intensively sampled substudy participants. By more frequent sampling, which allowed determination of the delay in the onset of HIV-1 RNA decay, we determined the slope to be Ϫ1.03 d Ϫ1 , substantially more acute than the mean plasma virus load decay slope calculated from the day-0-7 decreases. Furthermore, the mean duration of the first phase of viral decay among the substudy participants was 4.1 days (range, 2.5-7.0 days), which is considerably shorter than the range of 7-10 days observed in previous studies of ritonavir monotherapy [5, 8] .
DISCUSSION
We embarked on this trial to test whether HAART regimens containing combinations of nucleoside reverse-transcriptase inhibitors and protease inhibitors had indeed reached maximal potency. We took advantage of our understanding of the relationship between changes in HIV-1 RNA levels that occur shortly after initiation of therapy and the degree of suppression of viral replication in vivo to assess the relative efficacy of a novel 4-drug regimen incorporating compounds of all 3 classes of antiretroviral agents available. For comparators, we chose 2 combination regimens incorporating nucleoside reverse-transcriptase inhibitors and protease inhibitors that provide identically matched cohorts for baseline characteristics. This is critical, because it has been suggested that the rate of change in HIV-1 RNA levels may be different in patients at different stages of infection [9] . Here we have demonstrated, by analyzing decreases in plasma HIV-1 RNA levels from day 0 to day 7, that the relative efficacy of antiretroviral regimens may be augmented substantially, by 25%-30%, although we must empha- size that our patient groups were relatively small and that the comparator regimens currently are less likely to be prescribed as initial therapy. In addition, these may be minimal estimates of the differences in relative potency; the results of the virologic substudy, in which more-intensive plasma virus load sampling was conducted, suggest that actual first-phase slopes may be considerably underestimated by the day-0-7 plasma viral decay slopes. This is because the simpler day-0-7 analysis neglects initial delays that are both pharmacologic and mechanistic and therefore tends to overestimate the length of the first phase.
We believe that to more accurately assess the potential differences between HAART regimens, study subjects with pansusceptible virus and matched baseline characteristics need to be treated and monitored intensively, as we have done in the virologic substudy. Identically performed sampling-intensive studies of plasma HIV-1 RNA changes in response to a variety of current HAART regimens should allow more accurate assessment of the relative efficacies of the regimens being evaluated. Such studies, now in the planning stages, will also address obvious concerns regarding the retrospective nature of this analysis.
We did not find a difference in mean day-0-7 slopes for subjects treated with regimen A during acute and early infection and for those in whom therapy was initiated during established infection, despite reports to the contrary published elsewhere [9] . Although the numbers of patients in these studies are small, this result echoes our observation in a study of 20 subjects receiving protease inhibitor monotherapy [5] . In that study, we could not discern consistent differences in first-phase slopes for patients with early disease (low virus load and high CD4 ϩ cell count) and those for patients with advanced disease (high virus load and low CD4 ϩ cell count). We believe the decay characteristics of the virus-producing activated CD4 ϩ T cells responsible for the bulk of particle production before treatment are not significantly different in these groups, despite differences in disease stage. This would suggest that the life span of these cells is the same early and later in the course of HIV-1 infection.
Although early changes in HIV-1 RNA levels may indicate relative antiviral activity, and although there are 2 reports that early changes in HIV-1 RNA levels correlate with later virologic response [10, 11] , we are well aware that this may not translate into more-effective long-term suppression of viral replication in vivo. Other factors may determine the durability of virologic suppression, and these merit further discussion. Adherence to and tolerability of medications have been shown to be associated with virologic outcome [12] . It has already been observed that the use of 4-drug regimens may reduce patient acceptability and result in an inferior virologic outcome, compared with that achieved by 3-drug combinations [13] . It is also possible that changes in metabolism via induction of the cytochrome P450 system or changes in drug interactions over time may also be a factor in long-term suppression of viral replication. Finally, induction of enzyme systems, such as multidrug-resistance proteins, may affect intracellular drug levels, thereby affecting the durability of suppression of viral replication over time [14] . Longitudinal assessments of patients treated with regimens A and B are currently in progress to determine whether the differences in relative efficacy indicated by initial decreases in plasma HIV-1 RNA levels do, in fact, translate into enhanced in vivo suppression of viral replication over the long term.
Despite these reservations, we believe that our data are of substantial importance to HIV-1 therapeutics, clinical trial design, and drug development. The current treatment paradigm of indefinite HAART is complicated by drug toxicities, drug resistance, treatment fatigue, and adherence issues [12] . These issues have motivated clinical investigators to seek alternatives, such as treatment interruptions and delayed initiation of treatment. However, attempts to discontinue therapy in the majority of HIV-1-infected individuals treated with prolonged HAART have been disappointing [15, 16] . Maximally potent, optimized treatment regimens are critical requirements for development of alternatives that allow limited exposure to antiretroviral agents. Furthermore, we believe that, as new antiviral agents directed against existing and new targets are developed and the number of potential drug combinations increases, relative efficacy determinations may be useful in selecting specific combinations for larger comparative clinical trials.
